Stratec reports revenue decline in H1 2026
German diagnostics firm Stratec posts first-half revenue drop as demand softens in core markets.
Stratec SE, the German diagnostics and life sciences technology provider, reported a decline in revenue for the first half of 2026, citing softer demand in its core markets.
The company, which supplies automated systems for clinical diagnostics and bioprocessing, said total revenue fell by 4.2% year-on-year to €345.7 million in the six months ended June 30, 2026. Operating profit declined 7.1% to €68.3 million, while net profit decreased 8.5% to €45.2 million.
Stratec attributed the revenue decline to weaker order intake in Europe and North America, its two largest markets, as well as delays in project implementations. The company noted that while demand for its high-throughput systems remained stable, overall market conditions had softened due to economic uncertainty and budget constraints among customers.
Despite the revenue decline, Stratec maintained its full-year guidance, reaffirming its expectation for revenue growth of between 2% and 4% for the full year 2026. The company cited a strong order backlog and ongoing investments in automation and digitalization as supporting factors for its outlook.
Stratec’s shares were down 2.1% in early trading on the Frankfurt Stock Exchange following the announcement, underperforming the broader DAX index.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →